Rofecoxib- Tremeau Pharmaceuticals

Drug Profile

Rofecoxib- Tremeau Pharmaceuticals

Alternative Names: TRM 201

Latest Information Update: 05 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tremeau Pharmaceuticals
  • Class Antirheumatics; Lactones; Non-opioid analgesics; Sulfones
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Joint disorders
  • New Molecular Entity No

Highest Development Phases

  • Phase II Joint disorders

Most Recent Events

  • 05 Dec 2017 Chemical structure information added
  • 22 Nov 2017 Rofecoxib- Tremeau Pharmaceuticals receives Orphan Drug status for Joint disorders (haemophilic arthropathy) in USA
  • 21 Nov 2017 Phase-II clinical trials in Joint disorders (haemophilic arthropathy) in USA (unspecified route), before November 2017 (Tremeau Pharmaceuticals pipeline, November 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top